Earnings Releases·Nov 4, 2026, 4:01 PM ET

Niagen Bioscience — Third Quarter 2026 Earnings Summary

Total net sales declined to $27.2 million from $33.986 million in Q3 2025, resulting in a net loss of $1.2 million compared to net income of $4.578 million in the prior year period.
Adjusted EBITDA turned positive at $0.5 million, down from $6.361 million in Q3 2025, while operating cash flow for the nine-month period fell to $4.2 million from $12.825 million in the prior year.
Full-year 2026 guidance anticipates direct website revenue growth of 15% to 20% and overall e-commerce growth of approximately 5%, though the ingredient business is expected to remain lower than the prior year due to decreased partner volumes.
Strategic initiatives include the launch of Niagen™ Plus At-Home Injections and Tru Niagen® Skincare, expansion into Walmart.com, GNC, and Sam's Club, and a new clinical trial agreement with Mass General Brigham.
Management characterizes 2026 as an "investment year" with planned increases in operating expenses across commercial, research, and administrative functions to support growth in 2027 and beyond.